Search

Your search keyword '"Cerny, Jan"' showing total 942 results
Start Over Author "Cerny, Jan"
942 results on '"Cerny, Jan"'

105. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

Author

Wieduwilt, Matthew J., Metheny, Leland, Zhang, Mei-Jie, Wang, Hai-Lin, Estrada-Merly, Noel, Marks, David, I, Al-Homsi, A. Samer, Muffly, Lori, Chao, Nelson, Rizzieri, David, Gale, Robert Peter, Gadalla, Shahinaz M., Cairo, Mitchell, Mussetti, Alberto, Gore, Steven, Bhatt, Vijaya Raj, Patel, Sagar S., Michelis, Fotios, V, Inamoto, Yoshihiro, Badawy, Sherif M., Copelan, Edward, Palmisiano, Neil, Kharfan-Dabaja, Mohamed A., Lazarus, Hillard M., Ganguly, Siddhartha, Bredeson, Christopher, Diaz Perez, Miguel Angel, Cassaday, Ryan, Savani, Bipin N., Ballen, Karen, Martino, Rodrigo, Wirk, Baldeep, Bacher, Ulrike, Aljurf, Mahmoud, Bashey, Asad, Murthy, Hemant S., Yared, Jean A., Aldoss, Ibrahim, Farhadfar, Nosha, Liu, Hongtao, Abdel-Azim, Hisham, Waller, Edmund K., Solh, Melhem, Seftel, Matthew D., van der Poel, Marjolein, Grunwald, Michael R., Liesveld, Jane L., Kamble, Rammurti T., McGuirk, Joseph, Munker, Reinhold, Cahn, Jean-Yves, Lee, Jong Wook, Freytes, Cesar O., Krem, Maxwell M., Winestone, Lena E., Gergis, Usama, Nathan, Sunita, Olsson, Richard F., Verdonck, Leo F., Sharma, Akshay, Ringden, Olle, Friend, Brian D., Cerny, Jan, Choe, Hannah, Chhabra, Saurabh, Nishihori, Taiga, Seo, Sachiko, George, Biju, Baxter-Lowe, Lee Ann, Hildebrandt, Gerhard C., de Lima, Marcos, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Abid, Muhammad Bilal, Weisdorf, Daniel J., Saber, Wael, Wieduwilt, Matthew J., Metheny, Leland, Zhang, Mei-Jie, Wang, Hai-Lin, Estrada-Merly, Noel, Marks, David, I, Al-Homsi, A. Samer, Muffly, Lori, Chao, Nelson, Rizzieri, David, Gale, Robert Peter, Gadalla, Shahinaz M., Cairo, Mitchell, Mussetti, Alberto, Gore, Steven, Bhatt, Vijaya Raj, Patel, Sagar S., Michelis, Fotios, V, Inamoto, Yoshihiro, Badawy, Sherif M., Copelan, Edward, Palmisiano, Neil, Kharfan-Dabaja, Mohamed A., Lazarus, Hillard M., Ganguly, Siddhartha, Bredeson, Christopher, Diaz Perez, Miguel Angel, Cassaday, Ryan, Savani, Bipin N., Ballen, Karen, Martino, Rodrigo, Wirk, Baldeep, Bacher, Ulrike, Aljurf, Mahmoud, Bashey, Asad, Murthy, Hemant S., Yared, Jean A., Aldoss, Ibrahim, Farhadfar, Nosha, Liu, Hongtao, Abdel-Azim, Hisham, Waller, Edmund K., Solh, Melhem, Seftel, Matthew D., van der Poel, Marjolein, Grunwald, Michael R., Liesveld, Jane L., Kamble, Rammurti T., McGuirk, Joseph, Munker, Reinhold, Cahn, Jean-Yves, Lee, Jong Wook, Freytes, Cesar O., Krem, Maxwell M., Winestone, Lena E., Gergis, Usama, Nathan, Sunita, Olsson, Richard F., Verdonck, Leo F., Sharma, Akshay, Ringden, Olle, Friend, Brian D., Cerny, Jan, Choe, Hannah, Chhabra, Saurabh, Nishihori, Taiga, Seo, Sachiko, George, Biju, Baxter-Lowe, Lee Ann, Hildebrandt, Gerhard C., de Lima, Marcos, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Abid, Muhammad Bilal, Weisdorf, Daniel J., and Saber, Wael

Abstract

The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLAmatched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P <_ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P <_ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (<_18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.

Published
2022
Full Text
View/download PDF

106. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis

Author

Mei, Matthew, primary, Pillai, Raju, additional, Kim, Soyoung, additional, Estrada-Merly, Noel, additional, Afkhami, Michelle, additional, Yang, Lixin, additional, Meng, Zhuo, additional, Abid, Muhammad Bilal, additional, Aljurf, Mahmoud, additional, Bacher, Ulrike, additional, Beitinjaneh, Amer, additional, Bredeson, Christopher, additional, Cahn, Jean-Yves, additional, Cerny, Jan, additional, Copelan, Edward, additional, Cutler, Corey, additional, DeFilipp, Zachariah, additional, Diaz Perez, Miguel Angel, additional, Farhadfar, Nosha, additional, Freytes, César O., additional, Gadalla, Shahinaz M., additional, Ganguly, Siddhartha, additional, Gale, Robert Peter, additional, Gergis, Usama, additional, Grunwald, Michael R., additional, Hamilton, Betty K., additional, Hashmi, Shahrukh, additional, Hildebrandt, Gerhard C., additional, Lazarus, Hillard M., additional, Litzow, Mark, additional, Munker, Reinhold, additional, Murthy, Hemant S., additional, Nathan, Sunita, additional, Nishihori, Taiga, additional, Patel, Sagar S., additional, Rizzieri, David, additional, Seo, Sachiko, additional, Shah, Mithun Vinod, additional, Solh, Melhem, additional, Verdonck, Leo F., additional, Vij, Ravi, additional, Sobecks, Ronald M., additional, Oran, Betul, additional, Scott, Bart L., additional, Saber, Wael, additional, and Nakamura, Ryotaro, additional

Published
2022
Full Text
View/download PDF

108. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors

Author

Guru Murthy, Guru Subramanian, primary, Kim, Soyoung, additional, Hu, Zhen-Huan, additional, Estrada-Merly, Noel, additional, Abid, Muhammad Bilal, additional, Aljurf, Mahmoud, additional, Bacher, Ulrike, additional, Badawy, Sherif M., additional, Beitinjaneh, Amer, additional, Bredeson, Chris, additional, Cahn, Jean-Yves, additional, Cerny, Jan, additional, Diaz Perez, Miguel Angel, additional, Farhadfar, Nosha, additional, Gale, Robert Peter, additional, Ganguly, Siddhartha, additional, Gergis, Usama, additional, Hildebrandt, Gerhard C., additional, Grunwald, Michael R., additional, Hashmi, Shahrukh, additional, Hossain, Nasheed M., additional, Kalaycio, Matt, additional, Kamble, Rammurti T., additional, Kharfan-Dabaja, Mohamed A., additional, Hamilton, Betty Ky, additional, Lazarus, Hillard M., additional, Liesveld, Jane, additional, Litzow, Mark, additional, Marks, David I., additional, Murthy, Hemant S., additional, Nathan, Sunita, additional, Nazha, Aziz, additional, Nishihori, Taiga, additional, Patel, Sagar S., additional, Pawarode, Attaphol, additional, Rizzieri, David, additional, Savani, Bipin, additional, Seo, Sachiko, additional, Solh, Melhem, additional, Ustun, Celalettin, additional, van der Poel, Marjolein, additional, Verdonck, Leo F., additional, Vij, Ravi, additional, Wirk, Baldeep, additional, Oran, Betul, additional, Nakamura, Ryotaro, additional, Scott, Bart, additional, and Saber, Wael, additional

Published
2022
Full Text
View/download PDF

114. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients

Author

Oran, Betul, Ahn, Kwang Woo, Fretham, Caitrin, Beitinjaneh, Amer, Bashey, Asad, Pawarode, Attaphol, Wirk, Baldeep, Scott, Bart L, Savani, Bipin N, Bredeson, Christopher, Weisdorf, Daniel, Marks, David I, Rizzieri, David, Copelan, Edward, Hildebrandt, Gerhard C, Hale, Gregory A., Murthy, Hemant S, Lazarus, Hillard M, Cerny, Jan, Liesveld, Jane L, Yared, Jean A, Yves-Cahn, Jean, Szer, Jeffrey, Verdonck, Leo F, Aljurf, Mahmoud, van der Poel, Marjolein, Litzow, Mark, Kalaycio, Matt, Grunwald, Michael R, Diaz, Miguel Angel, Sabloff, Mitchell, Kharfan-Dabaja, Mohamed A, Majhail, Navneet S, Farhadfar, Nosha, Reshef, Ran, Olsson, Richard F, Gale, Robert Peter, Nakamura, Ryotaro, Seo, Sachiko, Chhabra, Saurabh, Hashmi, Shahrukh, Farhan, Shatha, Ganguly, Siddhartha, Nathan, Sunita, Nishihori, Taiga, Jain, Tania, Agrawal, Vaibhav, Bacher, Ulrike, Popat, Uday, and Saber, Wael

Subjects
Transplantation Conditioning, Myelodysplastic Syndromes, Graft vs Host Disease, Humans, Middle Aged, Busulfan, Melphalan, Survival Analysis, Article, Vidarabine, Aged
Abstract

Reduced-intensity conditioning (RIC) regimens developed to extend allogeneic stem cell transplantation (HSCT) to older patients have resulted in encouraging outcomes. We aimed to compare the two most commonly used RIC regimens, intravenous use of fludarabine with busulfan (FluBu) and fludarabine with melphalan (FluMel), in myelodysplastic syndrome (MDS). Through CIBMTR, we identified 1045 MDS patients aged ≥ 60 years who underwent first HSCT with a matched related or matched (8/8) unrelated donor using RIC. CIBMTR’s definition of RIC was used: a regimen that incorporated an intravenous busulfan total dose ≤ 7.2 mg/kg, or a low-dose melphalan total dose of ≤ 150 mg/m(2). The two groups, FluBu (n=697) and FluMel (n=448), were comparable for disease and transplant-related characteristics except for the more frequent use of anti-thymocyte globulin or alemtuzumab in the FluBu group (39% vs. 31%). The median age was 67 in both groups. FluMel was associated with a reduced relapse incidence (RI) compared with FluBu, with a 1-year adjusted incidence of 26% vs. 44% (p≤0.0001). Transplant-related mortality (TRM) was higher with FluMel compared with FluBu (26% vs. 16%, p≤0.0001). Since the magnitude of improvement with FluMel in RI was greater than the improvement in TRM with FluBu, disease-free survival (DFS) was improved at 1-year and beyond with FluMel compared with FluBu (48% vs. 40% at 1 year, p=0.02, and 35% vs. 27% at 3 years, p=0.01). Overall survival (OS) was comparable at 1 year (63% vs. 61%, p=0.4) but significantly improved with FluMel compared with FluBu at 3 years (46% vs. 39%, p=0.03). Our results suggest that FluMel is associated with superior DFS compared with FluBu due to reduced RI in older MDS patients.

Published
2021

120. Role of Immunomodulation of BCG Therapy on AML Remission

Author

Kennedy,Alice, Sahu,Kamal Kant, and Cerny,Jan

Subjects
International Medical Case Reports Journal
Abstract

Alice Kennedy,1 Kamal Kant Sahu,2 Jan Cerny3 1Department of Internal Medicine, University of Massachusetts Medical School, Worcester, MA, 01655, USA; 2Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA, 01608, USA; 3Division of Hematology and Oncology, Department of Internal Medicine, UMass Memorial Health Care, University of Massachusetts Medical School, Worcester, MA, 01655, USACorrespondence: Jan CernyDivision of Hematology and Oncology, Department of Internal Medicine, UMass Memorial Health Care, University of Massachusetts Medical School, Worcester, MA, 01655, USAEmail Jan.cerny@umassmemorial.orgAbstract: Bacillus Calmette–Guérin (BCG) has been studied in various cancers for its immune modulation. Although the mechanism is yet to be completely understood, we do have positive experiences in many oncological cases. Hereby, we present a case of an 82-year-old male with acute myeloid leukemia (AML) post allogeneic Stem Cell Transplants (AlloSCT) as a salvage therapy, now in remission, who presented with hematuria. Workup confirmed non-muscle invasive Bladder Cancer (NMIBC), for which he was treated with nine sessions of intravesical BCG therapy. During BCG treatment, the patient developed gradually increasing lymphocyte counts. Flowcytometry of a peripheral blood sample showed polyclonal cell lymphocytosis with CD8+ T-cell expansion. Although further work up his lymphocytosis to be polyclonal, it has persisted at follow-up for the last 4 years. Also, we did not find any evidence of leukemia recurrence at follow-up prompting us to associate the BCG use for this patient and it is role as immunomodulation to keep AML disease in remission.Keywords: cancer, bladder, leukemia, vaccine, immunity

Published
2021

121. Allogeneic Transplantation to Treat Therapy Related MDS and AML in Adults

Author

Metheny, Leland, Callander, Natalie S, Hall, Aric C, Zhang, Mei-Jei, Bo-Subait, Khalid, Wang, Hai-Lin, Agrawal, Vaibhav, Al-Homsi, A Samer, Assal, Amer, Bacher, Ulrike, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Bredeson, Chris, Byrne, Michael, Cairo, Mitchell, Cerny, Jan, DeFilipp, Zachariah, Perez, Miguel Angel Diaz, Freytes, César O, Ganguly, Siddhartha, Grunwald, Michael R, Hashmi, Shahrukh, Hildebrandt, Gerhard C, Inamoto, Yoshihiro, Kanakry, Christopher G, Kharfan-Dabaja, Mohamed A, Lazarus, Hillard M, Lee, Jong Wook, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F, Ringdén, Olov, Rizzieri, David, Savani, Bipin N, Savoie, Mary Lynn, Seo, Sachiko, van der Poel, Marjolein, Verdonck, Leo F, Wagner, John L, Yared, Jean A, Hourigan, Christopher S, Kebriaei, Partow, Litzow, Mark, Sandmaier, Brenda M, Saber, Wael, Weisdorf, Daniel, and de Lima, Marcos

Subjects
hemic and lymphatic diseases, 610 Medicine & health
Abstract

Patients who develop therapy-related myeloid neoplasm, either myelodysplastic syndrome (t-MDS) or acute myeloid leukemia (t-AML) have a poor prognosis. An earlier CIBMTR analysis of allogeneic hematopoietic cell therapy (allo-HCT) (n=868, 1990-2004) showed 5-year overall survival (OS) and disease-free survival (DFS) of 22% and 21%. Modern supportive care, graft versus host disease (GVHD) prophylaxis and reduced intensity conditioning (RIC) regimens have improved outcomes. Therefore, the Center for International Blood and Marrow Transplant Research (CIBMTR) analyzed 1531 allo-HCT for adults with t-MDS (n = 759) or t-AML (n = 772) performed from 2000 to 2014. Median age was 59 years (18-74) for t-MDS and 52 years (18-77) for t-AML. 24% of patient with t-MDS and 11% of patients with t-AML and had a prior autologous transplant. A myeloablative regimen was used in 49% of patients with t-MDS and 61% of patients with t-AML. Non-relapse mortality (NRM) at five years was 34% (95% confidence interval (CI) 30-37) and 34% (30-37) for t-MDS and t-AML, respectively. Relapse rates at five years were 46% (43-50) and 43% (40-47), respectively. 5-year OS and DFS was 27% (23-31) and 19% (16-23) for patients with t-MDS and 25% (22-28) and 23% (20-26) for patients with t-AML. In multivariate analysis, OS and DFS were significantly better in young patients with low risk t-MDS and those receiving MAC HCT during first complete remission (CR1) t-AML, but worse for those with prior autologous HCT, higher risk cytogenetics or IPSS-R score and partially matched unrelated donors (URD). Relapse remains the major cause of treatment failure with little improvement over the past two decades. These data indicate caution in recommending allo-HCT in these conditions and more effective anti-neoplastic approaches before and after allo-HCT. BACKGROUND Patients who develop therapy-related myeloid neoplasm, either myelodysplastic syndrome (t-MDS) or acute myeloid leukemia (t-AML) have a poor prognosis. An earlier CIBMTR analysis of allogeneic hematopoietic cell therapy (allo-HCT) (n=868, 1990-2004) showed 5-year overall survival (OS) and disease-free survival (DFS) of 22% and 21%. Modern supportive care, graft versus host disease (GVHD) prophylaxis and reduced intensity conditioning (RIC) regimens have improved outcomes. OBJECTIVES The primary objectives are OS and DFS. The secondary objectives are non-relapse mortality (NRM), relapse, GVHD rates and identifying prognostic factors for outcomes after allo-HCT. STUDY DESIGN The Center for International Blood and Marrow Transplant Research (CIBMTR) analyzed 1531 allo-HCT for adults with t-MDS (n = 759) or t-AML (n = 772) performed from 2000 to 2014. Cumulative incidence function was used to estimate relapse, NRM, acute and chronic GVHD. Kaplan-Meier estimate was used to calculate probabilities of OS and DFS. Cox proportional hazards regression model was used to estimate hazard ratio (HR) of patient / disease / transplant related factors for outcomes of interest. RESULTS The median age was 59 years (18-74) for t-MDS and 52 years (18-77) for t-AML. 24% of patient with t-MDS and 11% of patients with t-AML and had a prior autologous transplant. A myeloablative regimen was used in 49% of patients with t-MDS and 61% of patients with t-AML. Non-relapse mortality (NRM) at five years was 34% (95% confidence interval (CI) 30-37) and 34% (30-37) for t-MDS and t-AML, respectively. Relapse rates at five years were 46% (43-50) and 43% (40-47), respectively. 5-year OS and DFS was 27% (23-31) and 19% (16-23) for patients with t-MDS and 25% (22-28) and 23% (20-26) for patients with t-AML. In multivariate analysis, OS and DFS were significantly better in young patients with low risk t-MDS and those receiving MAC HCT during first complete remission (CR1) t-AML, but worse for those with prior autologous HCT, higher risk cytogenetics or IPSS-R score and partially matched unrelated donors (URD). CONCLUSIONS Relapse remains the major cause of treatment failure with little improvement over the past two decades. These data indicate caution in recommending allo-HCT in these conditions. Through better patient optimization, more effective conditioning and studies of post-HCT interventions, outcomes for patients with t-MDS and t-AML may improve.

Published
2021
Full Text
View/download PDF

122. Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia

Author

Patel, Shyam A., primary, Lloyd, Maxwell R., additional, Cerny, Jan, additional, Shi, Qiming, additional, Simin, Karl, additional, Ediriwickrema, Asiri, additional, Hutchinson, Lloyd, additional, Miron, Patricia M., additional, Higgins, Anne W., additional, Ramanathan, Muthalagu, additional, and Gerber, Jonathan M., additional

Published
2021
Full Text
View/download PDF

134. Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors

Author

Hong, Sanghee, Zhao, Jing, Wang, Shu, Wang, Han, Lee, Ji-Hyun, Farhadfar, Nosha, McGuirk, Joseph P., Savani, Bipin N., Shahrukh, Hashmi K., Stiff, Patrick, Khera, Nandita, Hahn, Theresa, Loren, Alison W., Jaglowski, Samantha M., Wood, William A., Saber, Wael, Cerny, Jan, Holtan, Shernan G., Reynolds, Jana M., Deol, Abhinav, Jim, Heather, Uberti, Joseph, Whalen, Victoria, Yi, Jean C., Preussler, Jaime, Baker, K. Scott, Shaw, Bronwen E., Devine, Steven, Syrjala, Karen, Majhail, Navneet S., Wingard, John R., and Al-Mansour, Zeina

Abstract

•As the use and outcomes of hematopoietic cell transplantation (HCT) for older patients has been increasing, it is important to study the effects of HCT on distress, psychosocial functioning, and health-related quality of life (HRQOL) in older HCT survivors, particularly to uncover areas that would benefit from targeted interventions.•Older survivors experienced a low level of distress and moderate-high level of confidence in survivorship information (CSI) at ≥1 year post-HCT.•Lower distress and higher CSI are associated with improved HRQOL and optimized preventive healthcare utilization, and thus distress scale and CSI measures can be used to individualize the care of older adult HCT survivors.

Published
2023
Full Text
View/download PDF

142. Retrospective Single Institution Comparative Study of Outcomes after Post-Transplant Cyclophosphamide for Haploidentical, Matched Unrelated, Mismatched Unrelated and Matched Sibling PB HSCT

Author

Wang, Mingjin, primary, Cerny, Jan, additional, Gerber, Jonathan M., additional, Patel, Shyam, additional, Gillis-Smith, Andrew, additional, Suzuki, Sakiko, additional, Shanahan, Lindsey, additional, Bednarik, Jayde, additional, Nath, Rajneesh, additional, and Ramanathan, Muthalagu, additional

Published
2021
Full Text
View/download PDF

144. Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma

Author

Dhakal, Binod, primary, D’Souza, Anita, additional, Callander, Natalie, additional, Chhabra, Saurabh, additional, Fraser, Raphael, additional, Davila, Omar, additional, Anderson, Kenneth, additional, Assal, Amer, additional, Badawy, Sherif M., additional, Berdeja, Jesus, additional, Cerny, Jan, additional, Comenzo, Raymond, additional, Chakraborty, Rajshekhar, additional, Peter Gale, Robert, additional, Kamble, Rammurti, additional, Kharfan‐Dabaja, Mohamed A., additional, Krem, Maxwell, additional, Ganguly, Siddhartha, additional, Janakiram, Murali, additional, Kansagra, Ankit, additional, Munker, Reinhold, additional, Murthy, Hemant, additional, Patel, Sagar, additional, Kumar, Shaji, additional, Shah, Nina, additional, Qazilbash, Muzaffar, additional, and Hari, Parameswaran, additional

Published
2020
Full Text
View/download PDF

145. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States

Author

Hong, Sanghee, primary, Brazauskas, Ruta, additional, Hebert, Kyle M., additional, Ganguly, Siddhartha, additional, Abdel‐Azim, Hisham, additional, Diaz, Miguel Angel, additional, Beattie, Sara, additional, Ciurea, Stefan O., additional, Szwajcer, David, additional, Badawy, Sherif M., additional, Gratwohl, Alois A., additional, LeMaistre, Charles, additional, Aljurf, Mahmoud D. S. M., additional, Olsson, Richard F., additional, Bhatt, Neel S., additional, Farhadfar, Nosha, additional, Yared, Jean A., additional, Yoshimi, Ayami, additional, Seo, Sachiko, additional, Gergis, Usama, additional, Beitinjaneh, Amer M., additional, Sharma, Akshay, additional, Lazarus, Hillard, additional, Law, Jason, additional, Ulrickson, Matthew, additional, Hashem, Hasan, additional, Schoemans, Hélène, additional, Cerny, Jan, additional, Rizzieri, David, additional, Savani, Bipin N., additional, Kamble, Rammurti T., additional, Shaw, Bronwen E., additional, Khera, Nandita, additional, Wood, William A., additional, Hashmi, Shahrukh, additional, Hahn, Theresa, additional, Lee, Stephanie J., additional, Rizzo, J. Douglas, additional, Majhail, Navneet S., additional, and Saber, Wael, additional

Published
2020
Full Text
View/download PDF

150. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide

Author

Im, Annie, primary, Rashidi, Armin, additional, Wang, Tao, additional, Hemmer, Michael, additional, MacMillan, Margaret L., additional, Pidala, Joseph, additional, Jagasia, Madan, additional, Pavletic, Steven, additional, Majhail, Navneet S., additional, Weisdorf, Daniel, additional, Abdel-Azim, Hisham, additional, Agrawal, Vaibhav, additional, Al-Homsi, A. Samer, additional, Aljurf, Mahmoud, additional, Askar, Medhat, additional, Auletta, Jeffery J., additional, Bashey, Asad, additional, Beitinjaneh, Amer, additional, Bhatt, Vijaya Raj, additional, Byrne, Michael, additional, Cahn, Jean-Yves, additional, Cairo, Mitchell, additional, Castillo, Paul, additional, Cerny, Jan, additional, Chhabra, Saurabh, additional, Choe, Hannah, additional, Ciurea, Stefan, additional, Daly, Andrew, additional, Perez, Miguel Angel Diaz, additional, Farhadfar, Nosha, additional, Gadalla, Shahinaz M., additional, Gale, Robert, additional, Ganguly, Siddhartha, additional, Gergis, Usama, additional, Hanna, Rabi, additional, Hematti, Peiman, additional, Herzig, Roger, additional, Hildebrandt, Gerhard C., additional, Lad, Deepesh P., additional, Lee, Catherine, additional, Lehmann, Leslie, additional, Lekakis, Lazaros, additional, Kamble, Rammurti T., additional, Kharfan-Dabaja, Mohamed A., additional, Khandelwal, Pooja, additional, Martino, Rodrigo, additional, Murthy, Hemant S., additional, Nishihori, Taiga, additional, O'Brien, Tracey A., additional, Olsson, Richard F., additional, Patel, Sagar S., additional, Perales, Miguel-Angel, additional, Prestidge, Tim, additional, Qayed, Muna, additional, Romee, Rizwan, additional, Schoemans, Hélène, additional, Seo, Sachiko, additional, Sharma, Akshay, additional, Solh, Melhem, additional, Strair, Roger, additional, Teshima, Takanori, additional, Urbano-Ispizua, Alvaro, additional, Van der Poel, Marjolein, additional, Vij, Ravi, additional, Wagner, John L., additional, William, Basem, additional, Wirk, Baldeep, additional, Yared, Jean A., additional, Spellman, Steve R., additional, Arora, Mukta, additional, and Hamilton, Betty K., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results